US stock · Healthcare sector · Medical Instruments & Supplies
Company Logo

Becton, Dickinson and Company

BDXNYSE

252.16

USD
-5.29
(-2.05%)
Pre Market
39.81P/E
21Forward P/E
1.54P/E to S&P500
71.882BMarket CAP
1.32%Div Yield
Upcoming Earnings
3 Aug-8 Aug
Shares Short
5/13/22
4.25M
Short % of Float
1.49%
Short % of Shares Outs.
1.49%
% Held by Insiders
0.82%
% Held by Institutions
85.87%
Beta
0.65
PEG Ratio
4.69
52w. high/low
277.29/229.40
Avg. Daily Volume
1.23M
Return %
Stock
S&P 500
1 year
7.11
(6.01)
3 years
9.42
39.24
5 years
38.56
63.25
Scale: |
High
Low
83.80
67.61
90.97
56.72
78.02
58.93
83.41
64.85
87.56
67.89
78.60
69.81
108.23
76.81
139.08
102.64
153.66
125.73
177.33
126.34
224.09
157.56
259.39
203.53
268.76
205.58
279.73
192.93
260.85
229.40
277.29
240.90
Currency: USD
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Revenue per share
23.58
25.94
29.29
29.78
31.46
35.40
37.52
41.27
43.69
50.77
58.69
55.23
61.86
64.05
61.36
69.99
69.98
Earnings per share
3.04
3.63
4.61
5.12
5.62
5.75
5.69
6.63
6.13
3.43
4.59
5.02
1.20
4.57
3.13
7.23
6.47
FCF per share
2.40
2.70
4.24
4.23
4.74
5.02
5.87
4.71
5.64
5.41
8.66
8.33
7.63
8.78
9.78
11.81
6.63
Dividends per share
0.86
0.98
1.14
1.32
1.48
1.63
1.79
1.98
2.18
2.39
2.64
3.09
3.59
3.65
3.68
3.62
3.71
CAPEX per share
1.95
2.36
2.67
2.91
2.70
2.74
2.69
3.01
3.38
3.13
3.38
3.32
3.46
3.55
2.90
4.26
4.01
Book Value per sh.
15.50
17.79
20.20
21.39
23.19
21.83
20.13
25.84
26.14
35.38
35.89
59.14
81.26
78.10
85.19
81.85
84.29
Comm.Shares outs.
247
245
244
240
234
221
205
195
193
203
213
219
258
270
279
289
286
Avg. annual P/E ratio
21.1
21.0
17.1
13.1
13.0
13.6
13.1
14.4
18.9
40.8
34.6
37.7
191.2
52.6
76.8
33.5
39.8
P/E to S&P500
1.2
1.2
0.8
0.2
0.6
0.8
0.9
0.8
1.0
2.0
1.6
1.6
7.7
2.2
2.0
1.1
1.5
Avg. annual div. yield
1.3%
1.3%
1.4%
2.0%
2.0%
2.1%
2.4%
2.1%
1.9%
1.7%
1.7%
1.6%
1.6%
1.5%
1.5%
1.5%
1.5%
Revenue (m)
5,835
6,360
7,156
7,161
7,372
7,829
7,708
8,054
8,446
10,282
12,483
12,093
15,983
17,290
17,117
20,248
20,031
Operating margin
18.0%
18.9%
21.7%
23.0%
22.7%
22.5%
20.2%
15.6%
19.0%
10.4%
11.5%
12.2%
9.4%
10.2%
8.7%
13.8%
13.0%
Depreciation (m)
405
441
477
470
502
504
511
546
562
891
1,114
1,088
1,978
2,253
2,154
2,273
2,274
Net profit (m)
752
890
1,127
1,232
1,318
1,271
1,170
1,293
1,185
695
976
1,100
311
1,233
874
2,092
1,921
Income tax rate
27.0%
28.9%
27.4%
26.0%
29.2%
26.3%
24.6%
20.3%
22.1%
6.0%
9.0%
(12.7)%
73.5%
(4.8)%
11.3%
6.7%
5.1%
Net profit margin
12.9%
14.0%
15.7%
17.2%
17.9%
16.2%
15.2%
16.1%
14.0%
6.8%
7.8%
9.1%
1.9%
7.1%
5.1%
10.3%
9.6%
Working capital (m)
1,609
1,652
2,198
2,870
2,834
2,845
3,344
3,743
3,896
1,659
1,967
15,291
195
1,009
3,133
2,212
3,495
Long-term debt (m)
957
956
953
1,488
1,495
2,485
3,761
3,763
3,768
11,370
10,550
18,667
18,894
18,081
17,224
17,110
17,584
Equity (m)
3,836
4,362
4,936
5,143
5,435
4,828
4,136
5,042
5,053
7,165
7,634
12,948
20,994
21,082
23,765
23,677
24,525
ROIC
14.4%
15.0%
17.4%
16.7%
16.5%
15.5%
13.4%
13.3%
12.6%
4.7%
6.3%
4.9%
1.1%
4.1%
2.8%
5.4%
4.9%
Return on capital
15.1%
16.9%
19.6%
18.3%
19.2%
17.3%
14.7%
13.7%
13.3%
4.1%
5.7%
4.0%
3.5%
3.5%
2.8%
5.0%
4.5%
Return on equity
19.6%
20.4%
22.8%
23.9%
24.2%
26.3%
28.3%
25.6%
23.5%
9.7%
12.8%
8.5%
1.5%
5.8%
3.7%
8.8%
7.8%
Plowback ratio
71.8%
73.1%
75.3%
74.3%
73.8%
71.6%
68.6%
70.1%
64.5%
30.2%
42.4%
38.5%
(198.1)%
20.2%
(17.4)%
49.9%
44.8%
Div.&Repurch./FCF
86.4%
84.5%
62.1%
82.1%
94.0%
160.0%
30.5%
42.0%
38.6%
44.3%
30.5%
37.1%
47.1%
21.0%
(69.3)%
81.9%
95.5%
Capital Structure
5 May · 2022 | Q2
All numbers in millions
Total liabilities
$ 30,261
Total assets
$ 54,786
Long-term debt
$ 17,584
Cash and equiv.
$ 3,147
Goodwill
$ 24,096
Retained earnings
$ 14,416
Common stock
285
Enterprise Value
$ 86,319
Working Capital
Currency: USD, in millions
2019
2020
2021
Cash & Investments
566
2,845
2,295
Receivables
2,345
2,398
2,497
Inventory
2,579
2,743
2,866
Other
1,174
3,272
2,927
Current assets
6,664
8,969
8,838
Acc. Payable
1,092
1,355
1,793
Debt due
1,309
706
500
Other
3,254
3,775
4,333
Current liabilities
5,655
5,836
6,626
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
18.29%
14.41%
11.89%
Cash flow
25.17%
17.17%
14.56%
Earnings
139.36%
83.74%
38.77%
Dividends
2.14%
12.37%
12.79%
Book value
(0.37)%
18.73%
23.89%
Insider Trading
Type
Shares
Date
Byington Carrie L
Award
107
05/06/22
Jones Christopher Ian Montague
Award
107
05/06/22
Hickey David
Sale
475
05/06/22
Neal Shana Carol
Award
7,525
04/06/22
Ezell Antoine C
InKind
610
03/02/22
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
4,225
4,253
3,855
4,784
17,117
2021
5,315
4,907
4,890
5,135
20,247
2022
4,995
5,011
- -
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
1.00
0.66
1.03
0.46
3.14
2021
3.47
1.03
1.81
0.92
7.23
2022
2.38
1.59
- -
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
0.91
0.91
0.96
- -
- -
2021
0.91
0.91
0.90
0.90
3.62
2022
0.95
0.95
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Medical Instruments & Supplies
CEO:
Mr. Thomas Polen
Full-time employees:
75,000
City:
Franklin Lakes
Address:
1 Becton Dr
IPO:
Sep 25, 1963
Website:
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Recent News